Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice☆
References (12)
- et al.
Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction
Am J Med
(1988) - et al.
Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomesa nationwide perspective of current clinical practice
Am Heart J
(1998) - et al.
Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
Lancet
(1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
N Engl J Med
(1993)Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarctionISIS-2
Lancet
(1988)A randomised comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction
Lancet
(1992)
Cited by (29)
Twenty-Five-Year (1986-2011) Trends in the Incidence and Death Rates of Stroke Complicating Acute Myocardial Infarction
2018, American Journal of MedicineCitation Excerpt :Moreover, patients who developed a stroke were more likely to have developed important in-hospital complications including atrial fibrillation and heart failure. These findings are consistent with the results of previously published studies.1,5,12,17,33,34 Despite our enhanced understanding of several risk factors for acute stroke in the setting of acute myocardial infarction, the mechanisms underlying the development of this acute neurologic event remain somewhat speculative.35,36
Purtscher-like retinopathy – A rare complication of acute myocardial infarction and a review of the literature
2017, Saudi Journal of OphthalmologyCitation Excerpt :This was also associated with the patient suffering a TIA. The incidence of a TIA or stroke after an acute MI is in the range of 1–2%.66–68 While never reported before, as these 2 conditions share similar pathogenic mechanisms, there may be significant under-reporting of the incidence of PUR especially in post-MI patients.
Cardioembolic Stroke and Postmyocardial Infarction Stroke
2016, Cardiology ClinicsCitation Excerpt :The stroke risk is increased up to 44-fold within the first month but is also increased 3 years after the acute event.9 The incidence of stroke during a hospital stay after acute coronary syndrome ranges from 0.7% to 2.2%.10–15 Hachet and colleagues16 reported the results of 8485 patients admitted to their intensive care unit for AMI between 2001 and 2010.
Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
2008, ChestCitation Excerpt :This stems, in part, from the fact that in many trials, the use of prior transient ischemic attack or stroke as an exclusion criterion has varied. In the prospective, observational German Myocardial Infarction Registry and Maximal Individual Therapy in Acute Myocardial Infarction registries, previous stroke within 3 months was the strongest predictor of stroke (OR, 9.3; 95% CI, 6 to 14.2) after STE MI.87 Similarly, in the prospective, observational FASTRAK II registry, a previous cerebrovascular event (stroke or transient ischemic attack) was an independent predictor of ICH (OR, 2.4; 95% CI, 1.3 to 4.7).88
The incidence of stroke after myocardial infarction: A meta-analysis
2006, American Journal of MedicineCitation Excerpt :For example, the study by Komrad et al18 was conducted from 1970 to 1981. Because this time frame is before the era of coronary artery reperfusion, the results may not be comparable with a contemporary MI population, such as those represented by the studies of Longstreth et al, Nakaoka et al, Puletti et al, Thompson and Robinson, and Wienbergen et al.19,20,28,33,34 While the study by Puletti et al28 was conducted in a similar time period, the smaller study population and geographic differences may explain the high stroke rate reported by Komrad in comparison.18 Similarly, Longstreth reported stroke rates that were higher than studies with similar design.19
- ☆
This study was supported in part by AstraZeneca, Wedel, Germany; Bristol-Myers Squibb, München, Germany; Knoll AG, Ludwigshafen, Germany; the Landesversichenrungsanstalt, Rheinland-Pfalz, Germany; and the Ministerum für Arbeit, Soziales und Gesundheit, Rheinland-Pfalz, Germany.